[{"begin": 179, "end": 192, "text": "Based Vaccine", "tokenized_text": "Based Vaccine", "type": "title", "id": 0}, {"begin": 194, "end": 218, "text": "Clinical Cancer Research", "tokenized_text": "Clinical Cancer Research", "type": "venue", "id": 1}, {"begin": 220, "end": 235, "text": "Clin Cancer Res", "tokenized_text": "Clin Cancer Res", "type": "venue", "id": 2}, {"begin": 236, "end": 240, "text": "1999", "tokenized_text": "1999", "type": "year", "id": 3}, {"begin": 0, "end": 60, "text": "Disis, M.L., Grabstein, K.H., Sleath, P.R., and M.A. Cheever", "tokenized_text": "Disis , M . L . , Grabstein , K . H . , Sleath , P . R . , and M . A . Cheever", "type": "authors", "id": 4}, {"begin": 60, "end": 178, "text": ": Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide", "tokenized_text": ": Generation of Immunity to the HER - 2 / neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide", "type": "title", "id": 5}]